ClinicalTrials.gg
RecruitingNCT06514456SUPAQ-IUpdated Jul 23, 2024

Italian Validation of the State Urge to be Physically Active- Questionnaire (SUPAQ-I) in Patients With Eating Disorders

An observational study in Feeding and Eating Disorders, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-23.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
210
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Feeding and Eating Disorders with a site in Italy — 13 open to participants now, 13 under way, none of them phase 3. Feeding and Eating Disorders · Italy.

Planned enrollment
4th of 10
210 · median 109
Started
2024
with 9 others
Observational
10 of 28
5 open now
Primary completion
2026-04
later than 8 of 12 live
Registered
10th of 28
by date
Lead sponsor
5 of 28
Istituto Auxologico Italiano

Among the 28 studies in Feeding and Eating Disorders with a site in Italy, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 10 that started in 2024, is one of 10 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 10th registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

13 of the 28 studies in Feeding and Eating Disorders with a site in Italy are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Feeding and Eating Disorders with a site in Italy, or all of them as a file.
02

Study summary

Eating disorders (EDs) are severe psychiatric conditions that cause significant health and psychosocial issues, with Anorexia Nervosa (AN) and Bulimia Nervosa (BN) having the highest mortality rates. The COVID-19 pandemic has led to an increase in ED cases, especially among children, with heightened restrictive eating and compulsive exercise. Up to 80% of individuals with AN engage in compulsive exercise, which current treatments fail to adequately address.

The State Urge to be Physically Active Questionnaire (SUPA-Q) is the only validated tool for assessing activity urges in ED patients, covering cognitive, emotional, and behavioral aspects. This study aims to develop and validate an Italian version of the SUPA-Q (SUPAQ-I) in a clinical sample of ED patients.

A mixed-longitudinal study design will be used, with assessments at admission (T0) and discharge (T1) to evaluate the SUPAQ-I's reliability, validity, and sensitivity to change. The sample will include patients aged 16-65 diagnosed with EDs undergoing inpatient rehabilitation. Statistical analyses will include exploratory and confirmatory factor analyses, and internal consistency will be measured using Cronbach's α and McDonald's Ω indices.

Validating the SUPAQ-I will improve the assessment of activity urges in ED patients, enhancing treatment strategies and outcomes.

Read the detailed description

Eating disorders (EDs) are characterized by a persistent disturbance of eating or eating-related behaviour resulting in altered consumption or absorption of food and leading to both life-threatening somatic complications and psychosocial impairment. Like most psychiatric disorders, EDs underlie pathogenetic mechanisms implying the interaction of neurobiological and genetic factors with the environment. EDs cause over 3000 deaths per year with worsening illness course and increasing chronic cases. For people suffering from EDs, quality of life is reduced and yearly healthcare costs are 48% higher than in the general population. Specifically, Anorexia Nervosa and Bulimia Nervosa report the highest mortality rates among EDs and psychiatric disorders in general. Following the outbreak of Covid-19 pandemic, a concerning increase in both hospital admissions rates and outpatient visits was reported worldwide especially in paediatric populations. Along with this surge in ED cases, changes in symptoms manifestation were also reported, especially in terms of increase in restrictive eating, social media use, comorbid anxiety and depression symptoms and compulsive physical exercise. Food obsession, concerns about body shape and weight contribute to favour ED patients engagement in ritualised behaviours such as counting calories, frequent weighing and problematic physical activity (PA), in terms of frequency, duration and intensity. Notably, up to 80% of individuals with AN engage in voluntary compulsive exercise as a form of weight control. Simultaneously, on a neurobiological basis, starvation appear to heightened the urge to move and restlessness in AN. Current interventions for AN primarily focus on addressing various facets of eating disorders, but treatments exhibit limited efficacy in targeting physical exercise, despite the growing recognition of PA as a pivotal factor reinforcing eating pathology. The heightened restlessness activation in AN might also contribute to the overestimation of body size by enhancing proprioception. Thus far, there are just a few validated instruments to assess acute activity urges in ED patients, with the State Urge to be Physically Active Questionnaire (SUPA-Q), being the only one validated in this clinical population and covering several of the cognitive, emotional and specific behavioural aspects related to activity urges. The SUPA-Q, a 21-item self-report questionnaire, has demonstrated high consistency, reliability, as well as convergent, divergent and factorial validity. Sensitivity to change has also been tested (Cohen's d= 0.48). However, to the best of our knowledge, there has been only one validation study of the SUPA-Q. The objective of this study is to evaluate the psychometric properties of the Italian version of the SUPA-Q, and to test its validity in a clinical sample of patients with EDs.

03

Conditions studied

  • Feeding and Eating Disorders

Keywords

  • Eating Disorders
  • State Urge to be Physically Active
  • Anorexia Nervosa
  • Bulimia Nervosa
  • Binge Eating Disorder
  • Questionnaire Language Validation
  • Urge to move
  • Physical activity
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals of both biological sexes affected by ED who will take part in the multidisciplinary inpatient intensive rehabilitation treatment as offered by the U.O. dei Disturbi del Comportamento Alimentare, San Giuseppe Hospital, Piancavallo (VCO), Italy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age between 16 and 65 years old;
  • diagnosis of ED as per DSM 5 or TR
  • * range between 13 and 30 kg/m2 (depending on ED main diagnosis)
  • for the pediatric population BMI SDS** range is set between -3 and +3 SD from expected BMI for age and sex

Exclusion criteria

Exclusion criteria:

  • presence of other pathologies not associated with ED (i.e., neurodegenerative diseases);
  • severe psychopathologies other than ED (i.e., schizophrenia)

    • will be calculated using the following formula: weight (kg)/height (m2) **For the pediatric population, BMI SDS will also be calculated to adjust BMI according to growth curve charts for children and adolescents belonging to the Italian population
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
210 participants (estimated)
Patient registry
No

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Height

    height in mt

    Time frame: through study completion, an average of 24 months

  2. Weight

    Weight in kg

    Time frame: through study completion, an average of 24 months

  3. BMI

    body mass index (in kg/m2)

    Time frame: through study completion, an average of 24 months

  4. State Urge to be Physically Active Questionnaire Italian Version (SUPAQ-I)

    State Urge to be Physically Active Questionnaire Italian Version (SUPAQ-I): It consists of a 21-item self-report questionnaire on a 5-point Likert scale (not at all, very little somewhat, quite a bit, a great deal). Items are divided into four scales (burden, emotional aspects, cognitive aspects and motor aspects). The higher the score, the greater the restlessness and the "state" urge to be physically active. Min. score: 0; max. score: 84. A decrease in SUPAQ-I scores means a better outcome.

    Time frame: through study completion, an average of 24 months

Secondary outcomes

  1. Eating Disorder Inventory-3 (EDI-3)

    The questionnaire consists of 91 items evaluated on a six-point Likert scale (always, usually, often, sometimes, rarely, never). The 91 items are divided into twelve primary scales (three scales three refer specifically to the eating disorder: drive for thinness (min 7, max 42), bulimia (min 8, max 48), and body dissatisfaction (min 10, max 60); nine general psychological scales relevant but non-specific for eating disorders: low self-esteem (min 6, max 36), personal alienation (min 7, max 42), interpersonal insecurity (min 7, max 42), interpersonal alienation (min 7, max 42), interoceptive deficits (min 9, max 54), emotional dysregulation (min 8, max 48), perfectionism (min 6, max 36), asceticism (min 7, max 42), and maturity fears (min 8, max 48). The higher the score, the greater the severity of the symptoms. A decrease in EDI-3 scores means a better outcome.

    Time frame: through study completion, an average of 24 months

  2. Compulsive Exercise Test (CET)

    The CET consists of a 24-item self-administered questionnaire evaluated on a 6-point Likert scale from 0 (never true) to 5 (always true). Items are divided into four scales (avoidance, weight control, mood, lack of enjoyment and rigidity). The Italian version of the CET showed acceptable reliability (Cronbach's α coefficients for all the domains \> .70). The higher the score, the greater the "trait"-like compulsive physical activity (cut-off is set at 15 points). Min score: 0; max. score: 120. A decrease in CET scores means a better outcome.

    Time frame: through study completion, an average of 24 months

  3. Exercise Addiction Inventory - Revised (EAI-R)

    Exercise Addiction Inventory - Revised : The EAI-R consists of a 6-item self-report questionnaire evaluated on a 6-point Likert scale from 1 (strongly disagree) to 6 (strongly agree). The higher the score the strongest the exercise addiction risk. Min score: 6; max score: 36. A decrease in EAI-R scores means a better outcome.

    Time frame: through study completion, an average of 24 months

  4. Barratt Impulsiveness Scale (15 item) (BIS-15)

    Barratt Impulsiveness Scale (15 item): It consists of a 15-item self-report questionnaire evaluated on a 4-point Likert scale from 1 (rarely/never) to 4 (almost always/always). Items are divided into four scales (pure impulsivity, planning and thinking, lack of attention and concentration impulsive buying). The higher the total score, the greater impulsivity. Min score: 15; max score: 60. This questionnaire will be used to test for divergent validity of the SUPAQ-I.

    Time frame: through study completion, an average of 24 months

Other outcomes

  1. Age

    age in years

    Time frame: through study completion, an average of 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2026, 23 months after the start.

Of 61 non-industry observational studies under Feeding and Eating Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 95. This study's planned 23 months is below that.

Counting every sponsor, half of 64 studies reached it within 42 months; a quarter within 18 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jul 23, 2024
StartActual
May 7, 2024
Primary completionEst.
Apr 15, 2026
CompletionEst.
Apr 15, 2026
Last update
Jul 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06514456
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
May 7, 2024
Primary completion
Apr 15, 2026 (estimated)
Completion
Apr 15, 2026 (estimated)
Last update
Jul 23, 2024

Study contacts

Margherita Boltri, MSc
Contact
m.boltri@auxologico.it
+393405242239
Leonardo Mendolicchio, M.D.
principal investigator · IRCCS Istituto Auxologico Italiano

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion